NICE numbers at 20

Leela Barham takes a look at NICE’s stats on Technology Appraisals to see how the agency has changed over it’s 20-year history and what the future might hold.

NICE changes its mind on Novartis’ Kisqali for breast cancer

NICE recommends funding for psoriasis and type 1 diabetes dr...

Patients in England and Wales should soon be able to access AbbVie’s psoriasis drug Skyrizi after NICE recommended regular NHS funding.

NICE restores parity between Alnylam and Akcea on rare disea...

Report calls for European funding reform for gene therapies

New payment models, dedicated investment, and better health technology assessment are among a raft of changes needed to bring regenerative medicines to patients in Europe, according to a ne

AZ appeals against NICE rejection of Tagrisso in untreated l...

AstraZeneca is appealing against NICE’s decision not to recommend funding for its lung cancer drug Tagrisso (osimertinib) in untreated patients with epidermal growth factor receptor (EGFR)